iQIYI Files Its Annual Report on Form 20-F

BEIJING, March 14, 2024 (GLOBE NEWSWIRE) -- iQIYI, Inc. (Nasdaq: IQ) (“iQIYI” or the “Company”), a leading provider of online entertainment video services in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission on March 14, 2024, U.S. Eastern Time. The annual report can be accessed on the Company’s investor relations website at http://ir.iqiyi.com.

The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Investor Relations Department, iQIYI, Inc., 4/F, iQIYI Youth Center, Yoolee Plaza, No. 21, North Road of Workers' Stadium, Chaoyang District, Beijing 100027, People’s Republic of China.

About iQIYI, Inc.

iQIYI, Inc. is a leading provider of online entertainment video services in China. It combines creative talent with technology to foster an environment for continuous innovation and the production of blockbuster content. It produces, aggregates and distributes a wide variety of professionally produced content, as well as a broad spectrum of other video content in a variety of formats. The Company distinguishes itself in the online entertainment industry by its leading technology platform powered by advanced AI, big data analytics and other core proprietary technologies. iQIYI attracts a daily subscriber base of more than 100 million, and its diversified monetization model includes membership services, online advertising services, content distribution, online games, IP licensing, talent agency, online literature, etc.

For more information, please contact:Investor RelationsiQIYI, Inc. [email protected]

Source: iQIYI, Inc.

You May Also Be Interested In

• Kyungdong Pharmaceutical and Asimov Announce Completion of Cell Line Development Campaign for Biosimilar Antibody
• Ruvi AI Surpasses 60% of Phase 4 as AI Crypto Presale Continues Rapid Momentum Following Record-Breaking Phase 3
• Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera